AT13387 and Imatinib — Competitive Intelligence Brief

AT13387 and Imatinib (AT13387 and Imatinib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: tyrosine kinase inhibitor. Area: Oncology.

phase 2 tyrosine kinase inhibitor B-Raf V600E kinase, BCR-ABL, c-Kit, PDGFR Oncology Small molecule

Target snapshot

AT13387 and Imatinib (AT13387 and Imatinib) — Astex Pharmaceuticals, Inc.. AT13387 is a potent and selective inhibitor of the B-Raf V600E kinase, while Imatinib is a tyrosine kinase inhibitor targeting BCR-ABL, c-Kit, and PDGFR.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AT13387 and Imatinib TARGET	AT13387 and Imatinib	Astex Pharmaceuticals, Inc.	phase 2	tyrosine kinase inhibitor	B-Raf V600E kinase, BCR-ABL, c-Kit, PDGFR
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
Letybo®	Letybo®	Yuvell	marketed	FLT3 inhibitor / multi-targeted tyrosine kinase inhibitor	FLT3, JAK2
Vizimpro	Dacomitinib	Pfizer Inc.	marketed	Tyrosine kinase inhibitor (TKI); Pan-HER inhibitor	Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3
lorlatinib plus chemotherapy	lorlatinib plus chemotherapy	The First Affiliated Hospital of Guangzhou Medical University	marketed	ALK tyrosine kinase inhibitor (combination therapy)	ALK (anaplastic lymphoma kinase), ROS1
Erlotinib, Pemetrexed	Erlotinib, Pemetrexed	Hunan Province Tumor Hospital	marketed	EGFR tyrosine kinase inhibitor + antifolate antimetabolite	EGFR; thymidylate synthase and folate-dependent enzymes
Sequential Icotinib Plus Chemotherapy	Sequential Icotinib Plus Chemotherapy	Betta Pharmaceuticals Co., Ltd.	marketed	EGFR tyrosine kinase inhibitor	EGFR (epidermal growth factor receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (tyrosine kinase inhibitor class)

1. Centre Leon Berard · 2 drugs in this class
2. Akeso · 1 drug in this class
3. Astex Pharmaceuticals, Inc. · 1 drug in this class
4. Chengdu Zenitar Biomedical Technology Co., Ltd · 1 drug in this class
5. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
6. Jiangsu ShengDiYa Medicine Co., Ltd. · 1 drug in this class
7. Nanjing Leads Biolabs Co.,Ltd · 1 drug in this class
8. Ocular Therapeutix, Inc. · 1 drug in this class
9. Peking University Cancer Hospital & Institute · 1 drug in this class
10. Pfizer · 1 drug in this class